Ergocalciferol high dose therapy
Pro Research Analysisby 
Searched over 200M research papers
High Dose Ergocalciferol Therapy: Efficacy in Raising Vitamin D Levels
High dose ergocalciferol (vitamin D2) therapy has been shown to be more effective than standard or conventional dosing in rapidly correcting vitamin D deficiency across a range of populations, including children with epilepsy, hemodialysis patients, postmenopausal women, nursing home residents, and individuals with chronic kidney disease (CKD) or cystic fibrosis 1234+2 MORE. In these studies, high dose regimens consistently resulted in greater increases in serum 25-hydroxyvitamin D (25-OHD) levels and a higher proportion of patients achieving vitamin D sufficiency compared to standard dosing 1234+2 MORE.
High Dose Ergocalciferol in Special Populations
Epileptic Children and Adolescents
In children and adolescents with epilepsy on antiepileptic drugs, a regimen of 60,000 IU every 10 days for 90 days normalized vitamin D levels in 80.5% of patients, compared to only 36.6% with a standard dose of 20,000 IU every 10 days. No adverse events were reported .
Hemodialysis and CKD Patients
Among hemodialysis patients, doubling the recommended ergocalciferol dose for 8 weeks led to a significantly higher rate of vitamin D sufficiency (97.4% vs. 76.4%) and a greater reduction in parathyroid hormone (PTH) levels, without increased adverse events . Similarly, in CKD stage III-IV patients, high dose ergocalciferol improved vitamin D status and reduced PTH more effectively than standard dosing, with no significant changes in calcium, phosphate, or adverse effects . In advanced CKD (stage 4-5), high dose ergocalciferol (50,000 IU/week for 6 weeks) significantly increased vitamin D levels without affecting mineral homeostasis or causing harm .
Institutionalized and Elderly Populations
In institutionalized postmenopausal women, weekly high dose ergocalciferol (100,000 IU) for 12 weeks resulted in more subjects achieving optimal vitamin D levels compared to a standard dose (40,000 IU), especially in those with severe deficiency. No differences in muscle strength, mobility, or adverse events were observed between groups . Nursing home residents receiving 50,000 IU three times weekly for four weeks saw their vitamin D levels normalize safely and effectively, with no cases of hypercalcemia or other side effects .
Cystic Fibrosis and Multiple Sclerosis
Children and young adults with cystic fibrosis achieved therapeutic vitamin D levels in 94% of cases after a very high dose regimen (700,000 IU over 14 days), with no evidence of toxicity . In multiple sclerosis patients, high dose ergocalciferol (50,000 IU/day for 7-10 days, then weekly or biweekly) significantly increased vitamin D levels, whereas low dose cholecalciferol did not .
Systemic Lupus Erythematosus (SLE)
In SLE patients, high dose ergocalciferol (100,000 IU weekly for 4 weeks, then 40,000 IU weekly for 20 weeks) raised vitamin D levels significantly more than placebo. While disease activity was not reduced, more patients in the high dose group were able to lower their corticosteroid doses, and the regimen was safe .
Safety and Tolerability of High Dose Ergocalciferol
Across studies, high dose ergocalciferol was well tolerated, with no significant increase in adverse events, hypercalcemia, or disturbances in mineral metabolism compared to standard dosing 1234+3 MORE. Even very high single or short-term oral doses (up to 600,000 IU) were effective and safe for rapid correction of deficiency, with oral administration being more effective than intramuscular for initial increases in vitamin D levels .
Conclusion
High dose ergocalciferol therapy is consistently more effective than standard dosing for correcting vitamin D deficiency in diverse patient groups, including those with chronic illnesses and institutionalized elderly. The therapy is generally safe, with minimal risk of adverse effects or disturbances in mineral metabolism. High dose regimens are especially beneficial for patients with severe deficiency or those who have not responded to standard supplementation.
Sources and full results
Most relevant research papers on this topic